<p>Guardant Health（纳斯达克股票代码：GH - 获取免费报告）在周五发布的报告中，摩根大通将其目标价格从 130.00 美元上调至 135.00 美元，Benzinga 报道。该公司目前对该股票给予 “增持” 评级。摩根大通的目标价格暗示该股票相较于之前收盘价有 47.11% 的潜在上涨空间。</p>
<p>获取 <strong>Guardant Health</strong> 的最新提醒：</p>
<ul>
<li>4 只医疗股大幅上涨——还有更多上涨空间</li>
</ul>
<p>其他几家券商也对 GH 发表了评论。Stifel Nicolaus 将 Guardant Health 的目标价格从 120.00 美元上调至 130.00 美元，并在 2 月 20 日的报告中给予该公司 “买入” 评级。Canaccord Genuity Group 将 Guardant Health 的目标价格从 125.00 美元上调至 135.00 美元，并在 2 月 20 日的研究报告中给予该公司 “买入” 评级。花旗集团将 Guardant Health 的目标价格从 135.00 美元上调至 150.00 美元，并在 2 月 20 日的研究报告中给予该公司 “买入” 评级。富国银行将 Guardant Health 的目标价格从 120.00 美元上调至 125.00 美元，并在 2 月 20 日的报告中给予该股票 “增持” 评级。最后，Raymond James Financial 在 2 月 23 日的研究报告中重申了 “跑赢大盘” 评级，并设定了 129.00 美元的目标价格。十九位投资分析师对该股票给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，Guardant Health 目前的共识评级为 “适度买入”，共识目标价格为 129.16 美元。</p>
<p><strong>查看我们对 GH 的最新分析</strong></p>
<h2>Guardant Health 股价下跌 0.5%</h2>
<ul>
<li>解读颠覆：深入了解 Cathie Wood 的最新投资</li>
</ul>
<p>周五交易时，Guardant Health 的股票下跌 0.50 美元，报 91.77 美元。该股票的交易量为 1,737,746 股，而其平均交易量为 2,037,164 股。该股票的 50 日移动平均线为 88.93 美元，200 日移动平均线为 96.92 美元。Guardant Health 的 12 个月低点为 36.36 美元，12 个月高点为 120.74 美元。该公司的市值为 121.7 亿美元，市盈率为-27.68，贝塔值为 1.48。</p>
<p>Guardant Health（纳斯达克股票代码：GH - 获取免费报告）最后一次发布财报是在 2 月 19 日。该公司报告本季度每股收益（EPS）为-0.50 美元，低于分析师的共识预期-0.43 美元，差距为 0.07 美元。该公司本季度的收入为 2.8127 亿美元，而分析师预期为 2.6974 亿美元。该公司的季度收入同比增长 39.4%。在去年同期，该公司每股收益为-0.62 美元。整体来看，卖方分析师预测 Guardant Health 在本年度的每股收益将为-2.87 美元。</p>
<h2>Guardant Health 的内部买卖情况</h2>
<ul>
<li>3 只快速增长的股票分析师预计价格将翻倍</li>
</ul>
<p>在其他新闻中，首席财务官 Michael Brian Bell 于 3 月 16 日星期一出售了 3,000 股该公司的股票，交易价格为 87.04 美元，总价值为 261,120.00 美元。交易后，首席财务官直接持有该公司 43,601 股股票，价值约为 3,795,031.04 美元。此次交易代表其持股比例减少了 6.44%。该交易已在 SEC 的备案中披露，具体信息可在此链接查看。此外，董事 Medina Manuel Hidalgo 于 3 月 6 日星期五出售了 1,300 股该公司的股票，交易价格为 91.54 美元，总交易额为 119,002.00 美元。交易后，该董事在公司持有 1,193 股，价值为 109,207.22 美元。此次交易使其持股比例减少了 52.15%。有关此次出售的更多细节可在官方 SEC 披露中找到。在过去的 90 天内，内部人士已出售 8,596 股公司股票，价值 775,767 美元。目前，6.10% 的股票由公司内部人士持有。</p>
<h2>机构投资者对 Guardant Health 的看法</h2>
<p>一些大型投资者最近对 GH 的持仓进行了调整。先锋集团（Vanguard Group Inc.）在第四季度将其在 Guardant Health 的持仓提高了 2.1%。先锋集团目前持有该公司 12,160,768 股股票，价值 1,242,101,000 美元，之前在上一季度又购买了 251,939 股。T. Rowe Price Associates Inc. MD 在第四季度将其在 Guardant Health 的持仓增加了 33.5%。T. Rowe Price Associates Inc. MD 目前持有该公司 5,636,078 股股票，价值 575,670,000 美元，之前在上一季度又购买了 1,414,441 股。Baillie Gifford &amp; Co.在第三季度将其在 Guardant Health 的持仓增加了 6.6%。Baillie Gifford &amp; Co.目前持有该公司 5,127,692 股股票，价值 320,378,000 美元，之前在上一季度又收购了 317,906 股。富兰克林资源公司（Franklin Resources Inc.）在第四季度将其在 Guardant Health 的持仓提高了 14.9%。富兰克林资源公司目前持有该公司 3,361,547 股股票，价值 343,348,000 美元，之前在该期间又收购了 435,232 股。最后，Geode Capital Management LLC 在第四季度将其在 Guardant Health 的持仓提高了 9.4%。Geode Capital Management LLC 目前持有该公司 3,213,657 股股票，价值 328,297,000 美元，之前在该期间又收购了 277,001 股。目前 92.60% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>Guardant Health 的关键新闻</h2>
<p>以下是本周影响 Guardant Health 的关键新闻：</p>
<ul>
<li>积极情绪：2026 年第一季度收入和增长大幅超出预期——收入为 3.017 亿美元，同比增长约 48%；肿瘤学收入为 2.05 亿美元，检测量增长约 47%（约 86,000 个肿瘤学检测），显示出强劲的需求。Guardant Health 发布 2026 年第一季度财务结果</li>
<li>积极情绪：公司提高了 2026 财年的收入指引（大约在 13 亿美元范围内），这支持了未来收入的可见性，并支撑了股价的上涨。指引新闻稿</li>
<li>积极情绪：每股收益略好于预期——报告每股亏损为（0.45 美元），而市场共识约为（0.47 美元），这一小幅超出降低了近期因盈利意外带来的下行风险。Zacks：第一季度亏损，超出收入预期</li>
<li>中性情绪：管理层的评论和细节可供查阅——投资者可以查看收益幻灯片和完整的收益电话会议记录，以评估利润率轨迹、指引驱动因素和商业化节奏。收益电话会议记录第一季度幻灯片</li>
<li>消极情绪：公司在每股收益方面仍然处于亏损状态，市场共识仍然预期全年每股收益为负（分析师预测持续亏损），因此估值依赖于持续的收入执行和盈利能力的进展。第一季度财报快照</li>
<li>消极情绪：今天的交易仍然有些波动，成交量低于平均水平——如果未来几个季度未能达到高预期，请关注流动性和财报后的卖压。MSN 报道</li>
</ul>
<h2>Guardant Health 公司简介</h2>
<p>(获取免费报告)</p>
<p>Guardant Health, Inc 是一家专注于血液癌症诊断的精准肿瘤学公司。成立于 2012 年，总部位于加利福尼亚州红木城，该公司开发了使用循环肿瘤 DNA（ctDNA）对实体肿瘤患者的基因组变化进行分析的非侵入性检测。Guardant Health 的使命是通过向全球临床医生、制药合作伙伴和研究人员提供可操作的数据来推动癌症护理的进步。</p>
<p>公司的旗舰产品 Guardant360 是一种下一代测序（NGS）检测，旨在检测 70 多种与癌症相关的基因中的突变、拷贝数变化和特定融合。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们认为比 Guardant Health 更好的股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0g?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0g"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Guardant Health 吗？</h2>
<p>在考虑 Guardant Health 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Guardant Health 并不在名单上。</p>
<p>虽然 Guardant Health 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

2 倍做多纳斯达克生物技术 ETF - ProShares

医疗业 ETF - SPDR

<p>摩根大通已将 Guardant Health（纳斯达克代码：GH）的目标股价从 130 美元上调至 135 美元，维持 “增持” 评级。这表明该股相较于前一交易日收盘价有 47.11% 的潜在上涨空间。其他券商也提高了目标股价，普遍评级为 “适度买入”，目标价为 129.16 美元。Guardant Health 的股价下跌 0.5%，至 91.77 美元，市值为 121.7 亿美元。尽管未能达到每股收益预期，该公司报告的收入同比增长 39.4%</p>

<p>Guardant Health (NASDAQ:GH - Get Free Report) had its price objective lifted by research analysts at JPMorgan Chase &amp; Co. from $130.00 to $135.00 in a report issued on Friday,Benzinga reports. The firm currently has an &#34;overweight&#34; rating on the stock. JPMorgan Chase &amp; Co.'s price target would suggest a potential upside of 47.11% from the stock's previous close.</p>
<div class="lb-trans"><p>Guardant Health（纳斯达克股票代码：GH - 获取免费报告）在周五发布的报告中，摩根大通将其目标价格从 130.00 美元上调至 135.00 美元，Benzinga 报道。该公司目前对该股票给予 “增持” 评级。摩根大通的目标价格暗示该股票相较于之前收盘价有 47.11% 的潜在上涨空间。</p>
</div><p>Get <strong>Guardant Health</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Guardant Health</strong> 的最新提醒：</p>
</div><ul>
<li>4 Healthcare Stocks With Massive Gains—and More to Come</li>
</ul>
<div class="lb-trans"><ul>
<li>4 只医疗股大幅上涨——还有更多上涨空间</li>
</ul>
</div><p>Several other brokerages have also commented on GH. Stifel Nicolaus raised their price objective on Guardant Health from $120.00 to $130.00 and gave the company a &#34;buy&#34; rating in a report on Friday, February 20th. Canaccord Genuity Group increased their target price on Guardant Health from $125.00 to $135.00 and gave the company a &#34;buy&#34; rating in a research report on Friday, February 20th. Citigroup lifted their price target on shares of Guardant Health from $135.00 to $150.00 and gave the company a &#34;buy&#34; rating in a research note on Friday, February 20th. Wells Fargo &amp; Company boosted their price target on shares of Guardant Health from $120.00 to $125.00 and gave the stock an &#34;overweight&#34; rating in a report on Friday, February 20th. Finally, Raymond James Financial restated an &#34;outperform&#34; rating and set a $129.00 price objective on shares of Guardant Health in a research report on Monday, February 23rd. Nineteen investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Guardant Health currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $129.16.</p>
<div class="lb-trans"><p>其他几家券商也对 GH 发表了评论。Stifel Nicolaus 将 Guardant Health 的目标价格从 120.00 美元上调至 130.00 美元，并在 2 月 20 日的报告中给予该公司 “买入” 评级。Canaccord Genuity Group 将 Guardant Health 的目标价格从 125.00 美元上调至 135.00 美元，并在 2 月 20 日的研究报告中给予该公司 “买入” 评级。花旗集团将 Guardant Health 的目标价格从 135.00 美元上调至 150.00 美元，并在 2 月 20 日的研究报告中给予该公司 “买入” 评级。富国银行将 Guardant Health 的目标价格从 120.00 美元上调至 125.00 美元，并在 2 月 20 日的报告中给予该股票 “增持” 评级。最后，Raymond James Financial 在 2 月 23 日的研究报告中重申了 “跑赢大盘” 评级，并设定了 129.00 美元的目标价格。十九位投资分析师对该股票给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，Guardant Health 目前的共识评级为 “适度买入”，共识目标价格为 129.16 美元。</p>
</div><p><strong>View Our Latest Analysis on GH</strong></p>
<div class="lb-trans"><p><strong>查看我们对 GH 的最新分析</strong></p>
</div><h2>Guardant Health Trading Down 0.5%</h2>
<div class="lb-trans"><h2>Guardant Health 股价下跌 0.5%</h2>
</div><ul>
<li>Deciphering Disruption: Inside Cathie Wood's Latest Plays</li>
</ul>
<div class="lb-trans"><ul>
<li>解读颠覆：深入了解 Cathie Wood 的最新投资</li>
</ul>
</div><p>Shares of Guardant Health stock traded down $0.50 during trading hours on Friday, reaching $91.77. The stock had a trading volume of 1,737,746 shares, compared to its average volume of 2,037,164. The stock's 50 day moving average is $88.93 and its 200 day moving average is $96.92. Guardant Health has a twelve month low of $36.36 and a twelve month high of $120.74. The firm has a market capitalization of $12.17 billion, a PE ratio of -27.68 and a beta of 1.48.</p>
<div class="lb-trans"><p>周五交易时，Guardant Health 的股票下跌 0.50 美元，报 91.77 美元。该股票的交易量为 1,737,746 股，而其平均交易量为 2,037,164 股。该股票的 50 日移动平均线为 88.93 美元，200 日移动平均线为 96.92 美元。Guardant Health 的 12 个月低点为 36.36 美元，12 个月高点为 120.74 美元。该公司的市值为 121.7 亿美元，市盈率为-27.68，贝塔值为 1.48。</p>
</div><p>Guardant Health (NASDAQ:GH - Get Free Report) last posted its earnings results on Thursday, February 19th. The company reported ($0.50) EPS for the quarter, missing analysts' consensus estimates of ($0.43) by ($0.07). The firm had revenue of $281.27 million during the quarter, compared to analysts' expectations of $269.74 million. The firm's revenue for the quarter was up 39.4% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.62) EPS. As a group, sell-side analysts predict that Guardant Health will post -2.87 earnings per share for the current year.</p>
<div class="lb-trans"><p>Guardant Health（纳斯达克股票代码：GH - 获取免费报告）最后一次发布财报是在 2 月 19 日。该公司报告本季度每股收益（EPS）为-0.50 美元，低于分析师的共识预期-0.43 美元，差距为 0.07 美元。该公司本季度的收入为 2.8127 亿美元，而分析师预期为 2.6974 亿美元。该公司的季度收入同比增长 39.4%。在去年同期，该公司每股收益为-0.62 美元。整体来看，卖方分析师预测 Guardant Health 在本年度的每股收益将为-2.87 美元。</p>
</div><h2>Insider Buying and Selling at Guardant Health</h2>
<div class="lb-trans"><h2>Guardant Health 的内部买卖情况</h2>
</div><ul>
<li>3 Fast-Growing Stocks Analysts See Doubling in Price</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只快速增长的股票分析师预计价格将翻倍</li>
</ul>
</div><p>In other news, CFO Michael Brian Bell sold 3,000 shares of the firm's stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $87.04, for a total value of $261,120.00. Following the transaction, the chief financial officer directly owned 43,601 shares of the company's stock, valued at approximately $3,795,031.04. This trade represents a 6.44% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Medina Manuel Hidalgo sold 1,300 shares of the business's stock in a transaction dated Friday, March 6th. The stock was sold at an average price of $91.54, for a total transaction of $119,002.00. Following the transaction, the director owned 1,193 shares in the company, valued at $109,207.22. The trade was a 52.15% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 8,596 shares of company stock valued at $775,767 over the last ninety days. 6.10% of the stock is currently owned by corporate insiders.</p>
<div class="lb-trans"><p>在其他新闻中，首席财务官 Michael Brian Bell 于 3 月 16 日星期一出售了 3,000 股该公司的股票，交易价格为 87.04 美元，总价值为 261,120.00 美元。交易后，首席财务官直接持有该公司 43,601 股股票，价值约为 3,795,031.04 美元。此次交易代表其持股比例减少了 6.44%。该交易已在 SEC 的备案中披露，具体信息可在此链接查看。此外，董事 Medina Manuel Hidalgo 于 3 月 6 日星期五出售了 1,300 股该公司的股票，交易价格为 91.54 美元，总交易额为 119,002.00 美元。交易后，该董事在公司持有 1,193 股，价值为 109,207.22 美元。此次交易使其持股比例减少了 52.15%。有关此次出售的更多细节可在官方 SEC 披露中找到。在过去的 90 天内，内部人士已出售 8,596 股公司股票，价值 775,767 美元。目前，6.10% 的股票由公司内部人士持有。</p>
</div><h2>Institutional Investors Weigh In On Guardant Health</h2>
<div class="lb-trans"><h2>机构投资者对 Guardant Health 的看法</h2>
</div><p>A number of large investors have recently made changes to their positions in GH. Vanguard Group Inc. lifted its position in Guardant Health by 2.1% during the fourth quarter. Vanguard Group Inc. now owns 12,160,768 shares of the company's stock worth $1,242,101,000 after buying an additional 251,939 shares in the last quarter. Price T Rowe Associates Inc. MD grew its holdings in Guardant Health by 33.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 5,636,078 shares of the company's stock valued at $575,670,000 after buying an additional 1,414,441 shares in the last quarter. Baillie Gifford &amp; Co. increased its stake in shares of Guardant Health by 6.6% in the 3rd quarter. Baillie Gifford &amp; Co. now owns 5,127,692 shares of the company's stock worth $320,378,000 after acquiring an additional 317,906 shares during the last quarter. Franklin Resources Inc. raised its holdings in shares of Guardant Health by 14.9% during the 4th quarter. Franklin Resources Inc. now owns 3,361,547 shares of the company's stock worth $343,348,000 after acquiring an additional 435,232 shares during the period. Finally, Geode Capital Management LLC raised its holdings in shares of Guardant Health by 9.4% during the 4th quarter. Geode Capital Management LLC now owns 3,213,657 shares of the company's stock worth $328,297,000 after acquiring an additional 277,001 shares during the period. 92.60% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>一些大型投资者最近对 GH 的持仓进行了调整。先锋集团（Vanguard Group Inc.）在第四季度将其在 Guardant Health 的持仓提高了 2.1%。先锋集团目前持有该公司 12,160,768 股股票，价值 1,242,101,000 美元，之前在上一季度又购买了 251,939 股。T. Rowe Price Associates Inc. MD 在第四季度将其在 Guardant Health 的持仓增加了 33.5%。T. Rowe Price Associates Inc. MD 目前持有该公司 5,636,078 股股票，价值 575,670,000 美元，之前在上一季度又购买了 1,414,441 股。Baillie Gifford &amp; Co.在第三季度将其在 Guardant Health 的持仓增加了 6.6%。Baillie Gifford &amp; Co.目前持有该公司 5,127,692 股股票，价值 320,378,000 美元，之前在上一季度又收购了 317,906 股。富兰克林资源公司（Franklin Resources Inc.）在第四季度将其在 Guardant Health 的持仓提高了 14.9%。富兰克林资源公司目前持有该公司 3,361,547 股股票，价值 343,348,000 美元，之前在该期间又收购了 435,232 股。最后，Geode Capital Management LLC 在第四季度将其在 Guardant Health 的持仓提高了 9.4%。Geode Capital Management LLC 目前持有该公司 3,213,657 股股票，价值 328,297,000 美元，之前在该期间又收购了 277,001 股。目前 92.60% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>Key Guardant Health News</h2>
<div class="lb-trans"><h2>Guardant Health 的关键新闻</h2>
</div><p>Here are the key news stories impacting Guardant Health this week:</p>
<div class="lb-trans"><p>以下是本周影响 Guardant Health 的关键新闻：</p>
</div><ul>
<li>Positive Sentiment: Q1 revenue and growth materially beat expectations — revenue was $301.7M, up ~48% year-over-year; oncology revenue was $205M and test volume rose ~47% (≈86k oncology tests), signaling strong demand. Guardant Health Reports First Quarter 2026 Financial Results</li>
<li>Positive Sentiment: Company raised FY2026 revenue guidance (roughly to the ~$1.3B range), which supports forward revenue visibility and underpins the share-price rally. Guidance Press Release</li>
<li>Positive Sentiment: EPS slightly better than estimates — reported loss per share of ($0.45) vs. consensus around ($0.47), a modest beat that reduces near-term downside risk from earnings surprises. Zacks: Q1 Loss, Beats Revenue Estimates</li>
<li>Neutral Sentiment: Management commentary and detail are available — investors can review the earnings slide deck and the full earnings call transcript to assess margin trajectory, guidance drivers, and commercialization cadence. Earnings Call TranscriptQ1 Slide Deck</li>
<li>Negative Sentiment: Company remains unprofitable on an EPS basis and consensus still expects negative full-year EPS (analysts forecast continued losses), so valuation depends on sustained top-line execution and progress toward profitability. Q1 Earnings Snapshot</li>
<li>Negative Sentiment: Trading remains somewhat volatile and below average volume today versus typical averages — keep an eye on liquidity and post-earnings selling pressure if future quarters miss elevated expectations. MSN Coverage</li>
</ul>
<div class="lb-trans"><ul>
<li>积极情绪：2026 年第一季度收入和增长大幅超出预期——收入为 3.017 亿美元，同比增长约 48%；肿瘤学收入为 2.05 亿美元，检测量增长约 47%（约 86,000 个肿瘤学检测），显示出强劲的需求。Guardant Health 发布 2026 年第一季度财务结果</li>
<li>积极情绪：公司提高了 2026 财年的收入指引（大约在 13 亿美元范围内），这支持了未来收入的可见性，并支撑了股价的上涨。指引新闻稿</li>
<li>积极情绪：每股收益略好于预期——报告每股亏损为（0.45 美元），而市场共识约为（0.47 美元），这一小幅超出降低了近期因盈利意外带来的下行风险。Zacks：第一季度亏损，超出收入预期</li>
<li>中性情绪：管理层的评论和细节可供查阅——投资者可以查看收益幻灯片和完整的收益电话会议记录，以评估利润率轨迹、指引驱动因素和商业化节奏。收益电话会议记录第一季度幻灯片</li>
<li>消极情绪：公司在每股收益方面仍然处于亏损状态，市场共识仍然预期全年每股收益为负（分析师预测持续亏损），因此估值依赖于持续的收入执行和盈利能力的进展。第一季度财报快照</li>
<li>消极情绪：今天的交易仍然有些波动，成交量低于平均水平——如果未来几个季度未能达到高预期，请关注流动性和财报后的卖压。MSN 报道</li>
</ul>
</div><h2>Guardant Health Company Profile</h2>
<div class="lb-trans"><h2>Guardant Health 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health's mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.</p>
<div class="lb-trans"><p>Guardant Health, Inc 是一家专注于血液癌症诊断的精准肿瘤学公司。成立于 2012 年，总部位于加利福尼亚州红木城，该公司开发了使用循环肿瘤 DNA（ctDNA）对实体肿瘤患者的基因组变化进行分析的非侵入性检测。Guardant Health 的使命是通过向全球临床医生、制药合作伙伴和研究人员提供可操作的数据来推动癌症护理的进步。</p>
</div><p>The company's flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.</p>
<div class="lb-trans"><p>公司的旗舰产品 Guardant360 是一种下一代测序（NGS）检测，旨在检测 70 多种与癌症相关的基因中的突变、拷贝数变化和特定融合。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Guardant Health</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们认为比 Guardant Health 更好的股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0g" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=GH"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Guardant Health Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Guardant Health 吗？</h2>
</div><p>Before you consider Guardant Health, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Guardant Health 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Guardant Health wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Guardant Health 并不在名单上。</p>
</div><p>While Guardant Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Guardant Health 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Guardant Health (NASDAQ:GH) Stock

Market Beat

Guardant Health

生物科技 ETF - VanEck Vectors

纳斯达克生物科技指数 ETF - iShares Nasdaq

美国医疗保健供应商 ETF - iShares

基因改革 ETF - ARK

标普生物技术 ETF - SPDR

基因免疫&健康关怀 ETF - iShares

标普生物技术 3 倍做多 - Direxion

纽交所高增长板生物技术指数 ETF - First Trust

美国医药设备 ETF - iShares

医药突破 ETF - ALPS

动态生物技术与基因组 ETF - Invesco

摩根大通

Stifel Financial

花旗

富国银行

瑞杰金融

普信金融

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

STIFEL FINANCIAL CORP 6.125% DEP SHS REP 1/1000 NON CU PF SR C

Stifel Financial Pref Share SFB 5.2 10/15/47

STIFEL FINANCIAL CORP 6.25%NON CUM DEP SHS REP 1/1000TH SER B

STIFEL FINANCIAL CORP 4.50% DEP SHS REP 1/1000TH PREF SHS SR D

CITIGROUP INC 6.250 NON CUM SER II PFD WI

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

RAYMOND JAMES FINANCIAL INC 6.375%DEP SHS REP 1/40TH FXD FLTG SER B

摩根大通预测 Guardant Health（纳斯达克股票代码：GH）的股票将迎来强劲的价格升值